prnano
  • Menu
  • Articles
    • Communications
    • Editorials
    • Letters to the Editor
    • Perspective, Opinion, or Discussion
    • Policies
    • Research Articles
    • Reviews
    • Technical Notes
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • The Rising Talents List
  • Journal Policies
  • search

    Sorry, something went wrong. Please try your search again.
    ×

    • Articles
    • Blog posts

RSS Feed

Enter the URL below into your favorite RSS reader.

https://precisionnanomedicine.com/feed
×
Perspective, Opinion, or Discussion
Vol. 3, Issue 4, 2020 June 27, 2020 EDT

Launching stakeholder discussions on identified regulatory needs for nanotechnology-enabled health products

Blanka Halamoda-Kenzaoui , Helen Box , Merel van Elk , Sandra Gaitan , Robert E. Geertsma , Eusebio Gainza Lafuente , Andrew Owen , Angel del Pozo , Matthias Roesslein , Susanne Bremer-Hoffmann ,
  • terminology
  • regulatory challenges
  • follow-on medicinal products
  • nanosimilars
  • regulatory framework
  • nanomedical devices
  • nanomedicines
ccby-nc-sa-4.0 • https://doi.org/10.33218/001c.13521
prnano
Halamoda-Kenzaoui, Blanka, Helen Box, Merel van Elk, Sandra Gaitan, Robert E. Geertsma, Eusebio Gainza Lafuente, Andrew Owen, Angel del Pozo, Matthias Roesslein, and Susanne Bremer-Hoffmann. 2020. “Launching Stakeholder Discussions on Identified Regulatory Needs for Nanotechnology-Enabled Health Products.” Precision Nanomedicine 3 (4): 608–21. https://doi.org/10.33218/001c.13521.
Save article as...▾
  • PDF
  • XML
  • Citation (BibTeX)
Powered by Scholastica, the modern academic journal management system